Lyell Immunopharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Lyell Immunopharma Inc: Is Infosys Ltd. worth buying?
Item: Lyell Immunopharma Inc
Rating: 1.74966675
Author: Trendlyne DVM scores

about

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline include...

25.26 -0.58 (-2.24%)

43.87% Fall from 52W High

49,997

XNAS Volume

XNAS 23 Jan, 2026 4:30 PM (EST)

Not Eligible

Expensive Valuation

11.7 / 100

Technically Neutral

58.3 / 100

1Yr Price target upside is 17%

3 analysts

Lyell Immunopharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Lyell Immunopharma Inc Live Stock Price Today, Share Analysis and Chart

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline include...

43.87% Fall from 52W High

SWOT Analysis

Lyell Immunopharma Inc Live Price Chart